NYSE:NVS - Novartis News Headlines

$92.87
+0.07 (+0.08 %)
(As of 06/25/2019 01:31 PM ET)
Today's Range
$92.71
Now: $92.87
$93.65
50-Day Range
$80.42
MA: $86.37
$92.80
52-Week Range
$63.60
Now: $92.87
$93.34
Volume61,334 shs
Average Volume1.91 million shs
Market Capitalization$214.53 billion
P/E Ratio18.34
Dividend Yield1.99%
Beta0.56

Headlines

Novartis (NYSE NVS) News Headlines

Source:
DateHeadline
Novartis wins Gilenya reprieve as judge blocks generics, for now - ReutersNovartis wins Gilenya reprieve as judge blocks generics, for now - Reuters
www.reuters.com - June 25 at 12:02 PM
Novartis wins Gilenya reprieve as judge blocks generics, for nowNovartis wins Gilenya reprieve as judge blocks generics, for now
finance.yahoo.com - June 25 at 12:02 PM
BRIEF-Glenmark Pharmaceuticals To Partner With Novartis In Brazil - ReutersBRIEF-Glenmark Pharmaceuticals To Partner With Novartis In Brazil - Reuters
www.reuters.com - June 24 at 3:50 PM
The 5 Most Expensive Drugs In US: What You Should KnowThe 5 Most Expensive Drugs In US: What You Should Know
finance.yahoo.com - June 24 at 3:50 PM
U.S. group says Novartis MS drug price out of line with benefit - ReutersU.S. group says Novartis MS drug price out of line with benefit - Reuters
www.reuters.com - June 22 at 6:45 PM
Financial Survey: Beigene (NASDAQ:BGNE) vs. Novartis (NASDAQ:NVS)Financial Survey: Beigene (NASDAQ:BGNE) vs. Novartis (NASDAQ:NVS)
www.americanbankingnews.com - June 21 at 4:22 PM
Sarcoma: 2018 Market Spotlight - Novartis has the Highest Number of Completed Clinical Trials for Sarcoma, with 15 Trials - PRNewswireSarcoma: 2018 Market Spotlight - Novartis has the Highest Number of Completed Clinical Trials for Sarcoma, with 15 Trials - PRNewswire
www.prnewswire.com - June 21 at 10:18 AM
Sarcoma: 2018 Market Spotlight - Novartis has the Highest Number of Completed Clinical Trials for Sarcoma, with 15 Trials - Yahoo FinanceSarcoma: 2018 Market Spotlight - Novartis has the Highest Number of Completed Clinical Trials for Sarcoma, with 15 Trials - Yahoo Finance
finance.yahoo.com - June 20 at 8:04 PM
From generic drugs to gummies: Boulder CBD company buys Novartis pharmaceutical plant in Broomfield for $18.8MFrom generic drugs to gummies: Boulder CBD company buys Novartis pharmaceutical plant in Broomfield for $18.8M
finance.yahoo.com - June 20 at 8:04 PM
The World Market for Leukemia Therapeutics 2019-2024 - Novartis is Leading the Market, Owing to Its Strong Sales Channel & Innovative Therapies - Yahoo FinanceThe World Market for Leukemia Therapeutics 2019-2024 - Novartis is Leading the Market, Owing to Its Strong Sales Channel & Innovative Therapies - Yahoo Finance
finance.yahoo.com - June 20 at 9:49 AM
Ex-Novartis Pill Factory Gets a New Life Making CBD Products - BloombergEx-Novartis Pill Factory Gets a New Life Making CBD Products - Bloomberg
www.bloomberg.com - June 20 at 9:49 AM
Global Basal Cell Carcinoma Market Spotlight Report 2019 Featuring Sun Pharmaceutical, Novartis, Roche, & Valeant Pharmaceuticals - ResearchAndMarkets.com - Yahoo FinanceGlobal Basal Cell Carcinoma Market Spotlight Report 2019 Featuring Sun Pharmaceutical, Novartis, Roche, & Valeant Pharmaceuticals - ResearchAndMarkets.com - Yahoo Finance
finance.yahoo.com - June 19 at 8:24 AM
Online pharmacy flags possible new impurity in blood pressure drugOnline pharmacy flags possible new impurity in blood pressure drug
finance.yahoo.com - June 18 at 9:40 PM
Fourth Carcinogen Discovered in Heart Pills Used by Millions - BloombergFourth Carcinogen Discovered in Heart Pills Used by Millions - Bloomberg
www.bloomberg.com - June 18 at 4:39 PM
Myelofibrosis Market Spotlight 2017-2026: Novartis Leads Industry sponsors with the Highest Number of Clinical Trials, Followed by Incyte - ResearchAndMarkets.com - Business WireMyelofibrosis Market Spotlight 2017-2026: Novartis Leads Industry sponsors with the Highest Number of Clinical Trials, Followed by Incyte - ResearchAndMarkets.com - Business Wire
www.businesswire.com - June 18 at 4:39 PM
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz - Yahoo FinanceNovartis (NVS) Announces Promising Data on Tasigna & Hyrimoz - Yahoo Finance
finance.yahoo.com - June 18 at 6:43 AM
Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001) - GlobeNewswireNovartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001) - GlobeNewswire
www.globenewswire.com - June 15 at 5:59 AM
BRIEF-Novartis Says Sandoz’ Hyrimoz Phase III Study Meets Endpoints - ReutersBRIEF-Novartis Says Sandoz’ Hyrimoz Phase III Study Meets Endpoints - Reuters
www.reuters.com - June 15 at 5:59 AM
Novartis Makes Substantial Pipeline Progress On A Couple Of Fronts - Seeking AlphaNovartis Makes Substantial Pipeline Progress On A Couple Of Fronts - Seeking Alpha
seekingalpha.com - June 13 at 11:02 AM
Novartis Reports Data on Cosentyx for Psoriatic Arthritis - Yahoo FinanceNovartis Reports Data on Cosentyx for Psoriatic Arthritis - Yahoo Finance
finance.yahoo.com - June 13 at 11:02 AM
Ligand Inks Oncology Drug Discovery Deal With PhoreMostLigand Inks Oncology Drug Discovery Deal With PhoreMost
finance.yahoo.com - June 13 at 11:02 AM
Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show - GlobeNewswireCosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show - GlobeNewswire
globenewswire.com - June 12 at 7:51 PM
Roche's Rituxan Gets Priority Review for Blood DisorderRoche's Rituxan Gets Priority Review for Blood Disorder
finance.yahoo.com - June 12 at 7:51 PM
Novartis Kisqali Might Have A Path Forward To Take On Pfizers Ibrance - Seeking AlphaNovartis Kisqali Might Have A Path Forward To Take On Pfizer's Ibrance - Seeking Alpha
seekingalpha.com - June 12 at 9:44 AM
Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis - GlobeNewswireNovartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis - GlobeNewswire
globenewswire.com - June 12 at 9:44 AM
BRIEF-Novartis Says Cosentyx Shows Efficacy In Key Manifestations Of Psoriatic Arthritis - ReutersBRIEF-Novartis Says Cosentyx Shows Efficacy In Key Manifestations Of Psoriatic Arthritis - Reuters
www.reuters.com - June 12 at 9:44 AM
Novartiss Secret Settlement Talks Revealed in Accidental Filing - BloombergNovartis's Secret Settlement Talks Revealed in Accidental Filing - Bloomberg
www.bloomberg.com - June 11 at 7:36 PM
Sanofi appoints Novartis exec as new CEOSanofi appoints Novartis exec as new CEO
seekingalpha.com - June 9 at 8:12 AM
The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix - BenzingaThe Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix - Benzinga
www.benzinga.com - June 7 at 4:04 PM
Here’s What Hedge Funds Think About Novartis AG (NVS) - Yahoo FinanceHere’s What Hedge Funds Think About Novartis AG (NVS) - Yahoo Finance
finance.yahoo.com - June 7 at 4:04 PM
Novartis Appoints New Pharma Unit Head, Gives Other Updates - Yahoo FinanceNovartis Appoints New Pharma Unit Head, Gives Other Updates - Yahoo Finance
finance.yahoo.com - June 7 at 4:04 PM
Sanofi poised to appoint Novartis Hudson as CEO - ReutersSanofi poised to appoint Novartis' Hudson as CEO - Reuters
www.reuters.com - June 6 at 7:22 PM
BRIEF-Novartis Says Histology Data With Iscalimab Suggests Possible Extended Survival Of Transplanted Organs - ReutersBRIEF-Novartis Says Histology Data With Iscalimab Suggests Possible Extended Survival Of Transplanted Organs - Reuters
www.reuters.com - June 6 at 8:09 AM
Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible - Yahoo FinanceNovartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible - Yahoo Finance
finance.yahoo.com - June 6 at 8:09 AM
BRIEF-Novartis AG Says Long-Term Survival Benefit Shown For Metastatic Melanoma Patients Treated With Novartis Tafinlar + Mekinist - ReutersBRIEF-Novartis AG Says Long-Term Survival Benefit Shown For Metastatic Melanoma Patients Treated With Novartis Tafinlar + Mekinist - Reuters
www.reuters.com - June 5 at 7:06 PM
Novartis AG (NVS) Given Average Recommendation of "Hold" by AnalystsNovartis AG (NVS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 5 at 10:13 AM
Ophthalmology Market, 2025 - Major Players are Novartis, Bausch & Lomb, F.Hoffman La-Roche, Regeneron Pharmaceuticals, & Allergan - Yahoo FinanceOphthalmology Market, 2025 - Major Players are Novartis, Bausch & Lomb, F.Hoffman La-Roche, Regeneron Pharmaceuticals, & Allergan - Yahoo Finance
finance.yahoo.com - June 4 at 6:57 PM
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials - Yahoo FinanceNovartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials - Yahoo Finance
finance.yahoo.com - June 4 at 8:10 AM
Novartis (NVS) Announces Various Data Presentations at ASCO - Yahoo FinanceNovartis (NVS) Announces Various Data Presentations at ASCO - Yahoo Finance
finance.yahoo.com - June 4 at 8:10 AM
Novartis up 2% on updated capmatinib data - Novartis AG (NYSE:NVS) - Seeking AlphaNovartis up 2% on updated capmatinib data - Novartis AG (NYSE:NVS) - Seeking Alpha
seekingalpha.com - June 3 at 7:01 PM
Aduro Biotech (ADRO), Novartis AG (NVS) Report Data from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) - StreetInsider.comAduro Biotech (ADRO), Novartis AG (NVS) Report Data from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) - StreetInsider.com
www.streetinsider.com - June 3 at 8:05 AM
BRIEF-Novartis Announces New Data On Geometry Mono-1 Lung Cancer Study - ReutersBRIEF-Novartis Announces New Data On Geometry Mono-1 Lung Cancer Study - Reuters
www.reuters.com - June 3 at 8:05 AM
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials - PRNewswireNovartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials - PRNewswire
www.prnewswire.com - June 3 at 8:05 AM
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical TrialsNovartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
www.prnewswire.com - June 3 at 1:43 AM
BRIEF-Aduro Biotech And Novartis Present Results From Ongoing Phase 1B Study - ReutersBRIEF-Aduro Biotech And Novartis Present Results From Ongoing Phase 1B Study - Reuters
www.reuters.com - June 2 at 6:08 PM
Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas - GlobeNewswireAduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas - GlobeNewswire
globenewswire.com - June 2 at 6:08 PM
Is the $2.1 Million Price Tag for Novartis Zolgensma Ridiculous? - Motley FoolIs the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous? - Motley Fool
www.fool.com - June 1 at 8:10 AM
Novartis hopes Kisqali data will help narrow gap to blockbuster rivalNovartis hopes Kisqali data will help narrow gap to blockbuster rival
finance.yahoo.com - June 1 at 8:10 AM
Nationwide Childrens invented the most expensive drug ever, but the hospital didnt set the price - Columbus Business FirstNationwide Children's invented 'the most expensive drug ever,' but the hospital didn't set the price - Columbus Business First
www.bizjournals.com - May 31 at 7:03 PM
Novartis (NVS) Reports Positive Phase III Data on Asthma Drug - Yahoo FinanceNovartis (NVS) Reports Positive Phase III Data on Asthma Drug - Yahoo Finance
finance.yahoo.com - May 31 at 8:11 AM
This page was last updated on 6/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel